MedImmune and Abpro launch bispecific antibody spinout

AstraZeneca's biologics arm will help nurture spinoff AbMed in its early stages.

AstraZeneca’s biologics arm MedImmune and synthetic biology co Abpro have joined forces on a new Ang2-VEGF research collab that will come together under a new spinout.

The spinout, dubbed AbMed, will work on a preclinical, bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF), with Abpro helping it run day-to-day ops.

“Several potential therapeutic areas will be explored” where blocking the Ang2 and VEGF pathways with the bispecific antibody “may provide clinical benefit,” the companies said in a statement, although further detailed targets were not shared, except that it “may be useful in targeting disease indications with high unmet needs.”


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

AbMed will officially work as a subsidiary of Abpro, which is also set to take the lion’s share of global development and commercialization rights to the program, while MedImmune will gain future biobucks, as well as hold a minority equity stake in AbMed.

"This agreement arises out of MedImmune's culture of entrepreneurship and innovation—both in science and in business," said Jane Osbourn, VP of R&D at MedImmune. "We believe partners like Abpro can help us maximize our extensive preclinical portfolio to advance therapies for patients."

This comes after the beginning of some staff cuts from MedImmune over the summer as it looks toward a deeper focus (and a larger cash pile) for its oncology research.

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.